American Society of Clinical Oncology Genitourinary (ASCO GU) cancers symposium held in San Francisco, CA between February 13 ...
All nine patients treated with a personalized cancer vaccine following removal of their tumors remained cancer-free at a median data cut-off of 34.7 months.
(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Annual Symposium held in San Francisco, CA between February 13–15, 2025 was host to a case-based session ...
Casdatifan’s progression-free survival benefits could help differentiate it from Merck’s Welireg in the kidney cancer arena, ...
KAMR Amarillo on MSN8h
ASCO GU Symposium announces new findings on tumor reduction and survival outcomes in advanced renal cell carcinomaThomas E. Hutson, D.O., Pharm.D., Ph.D., chief of the Hematology Oncology Division in the Department of Internal Medicine at ...
The ideal indication for NSS in the presence of a normal contralateral kidney is, therefore, the presence of an easily resectable, small (4 cm diameter or less), solitary, exophytic renal tumor ...
Newly published detailed clinical trial data show why Exelixis abandoned a plan to seek an FDA approval for a combination of ...
Researchers evaluated a neoantigen-targeting personalized cancer vaccine in patients with high-risk, fully resected clear ...
Medical Xpress on MSN13d
Cancer vaccine shows promise for patients with stage III and IV kidney cancerDana-Farber Cancer Institute researchers report that all nine patients in a clinical trial being treated for stage III or IV ...
Share and Cite: Hinz, B. and Kenyon, J. (2025) Getting to a Diagnosis: A Rare Case of TFE3 Translocation Renal Cell Carcinoma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback